Literature DB >> 24890645

Multiple sclerosis: Does aggressive MS warrant aggressive treatment?

Mark S Freedman1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24890645     DOI： 10.1038/nrneurol.2014.98

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  9 in total

1.  'Time is brain' also in multiple sclerosis.

Authors:  Mark S Freedman
Journal:  Mult Scler       Date:  2009-10-06       Impact factor: 6.312

2.  Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.

Authors:  Joachim Burman; Ellen Iacobaeus; Anders Svenningsson; Jan Lycke; Martin Gunnarsson; Petra Nilsson; Magnus Vrethem; Sten Fredrikson; Claes Martin; Anna Sandstedt; Bertil Uggla; Stig Lenhoff; Jan-Erik Johansson; Cecilia Isaksson; Hans Hägglund; Kristina Carlson; Jan Fagius
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-02-19       Impact factor: 10.154

3.  Characterising aggressive multiple sclerosis.

Authors:  Suresh Menon; Afsaneh Shirani; Yinshan Zhao; Joel Oger; Anthony Traboulsee; Mark S Freedman; Helen Tremlett
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-06-06       Impact factor: 10.154

4.  Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.

Authors:  G Edan; G Comi; E Le Page; E Leray; M A Rocca; M Filippi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-03-24       Impact factor: 10.154

5.  The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.

Authors:  Antonio Scalfari; Anneke Neuhaus; Alexandra Degenhardt; George P Rice; Paolo A Muraro; Martin Daumer; George C Ebers
Journal:  Brain       Date:  2010-06-09       Impact factor: 13.501

6.  Immunosuppressive treatment in multiple sclerosis.

Authors:  Howard L Weiner
Journal:  J Neurol Sci       Date:  2004-08-15       Impact factor: 3.181

Review 7.  Treatment optimization in MS: Canadian MS Working Group updated recommendations.

Authors:  Mark S Freedman; Daniel Selchen; Douglas L Arnold; Alexandre Prat; Brenda Banwell; Michael Yeung; David Morgenthau; Yves Lapierre
Journal:  Can J Neurol Sci       Date:  2013-05       Impact factor: 2.104

8.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Authors:  Alasdair J Coles; Cary L Twyman; Douglas L Arnold; Jeffrey A Cohen; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Tamara Miller; Elizabeth Fisher; Rupert Sandbrink; Stephen L Lake; David H Margolin; Pedro Oyuela; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

9.  Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis.

Authors:  Nikolai Pfender; Riccardo Saccardi; Roland Martin
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.